Crescent Diagnostics is a clinical diagnostics firm developing a proprietary predictive test for osteoporosis - BQT®.
Osteoporosis-related fractures impose costs of €26bn in the EU and $19 bn in the US each year. Crescent is developing BQT, a 5-minute non-invasive predictive test for bone quality and hip fracture risk. This will enable clinicians to identify those who are at high risk of suffering a hip fracture – the most devastating consequence of osteoporosis. Appropriate interventions can then be made to help patients avoid this preventable disease.